Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study - PubMed
Full text linksCite Display options Display options Background: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC …